Europe Veterinary Vaccines Market Size, Growth, Share & Trends Analysis
Europe Veterinary Vaccines Market by Type (Porcine, Poultry, Livestock, Companion Animals), Technology (Live Attenuated, Inactivated, Toxoid), Route of Administration (Intramuscular, Subcutaneous, Oral), and End User (Hospitals, Clinics) – Forecast to 2031
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The Europe veterinary vaccines market, valued at US$3.84 billion in 2025, stood at US$4.08 billion in 2026 and is projected to advance at a resilient CAGR of 6.6% from 2026 to 2031, culminating in a forecasted valuation of US$5.61 billion by the end of the period. The growth of the market is driven by the increased pet ownership and greater emphasis on animal welfare. Additionally, the supporting legislation for preventing diseases has made vast government programs on animal health to further promote vaccination on companion animals as well as livestock. Other factors associated with introducing sustainable livestock practices and heightened food quality standards, coupled with their need for effective immunization solutions, will continue to be catalysts for market growth. Moreover, high development and compliance costs due to stringent regulations restrain market growth. This will also be a challenge for continued progress and acceptance of veterinary vaccine solutions throughout Europe while managing these drivers of growth.
KEY TAKEAWAYS
-
By RegionFrance is estimated to be the fastest-growing regional market in 2026.
-
By TypeThe livestock vaccines segment accounted for the largest share of 24.5% in 2025.
-
By DiseaseThe livestock diseases segment accounted for the largest share of 31.6% in 2025.
-
By Route of AdministrationThe subcutaneous route of administration segment accounted for largest share in 2025.
-
By TechnologyThe live attenuated vaccines segment accounted for the largest share of 41.5% in 2025.
-
Competitive LandscapeZoetis, Merck & Co, Inc., and Boehringer Ingelheim International GmbH are identified as STAR players in the market. These industry leaders have very broad vaccine portfolios, large-scale manufacturing, strong R&D, and global distribution.
-
Competitive LandscapeHIPRA, Hester Biosciences, and Vaxxinova are identified as high-growth innovators/SMEs. These companies are carving out a niche through regional specialization, novel vaccine technologies, and growing presence in emerging markets.
The Europe veterinary vaccine market is expected to remain poised for healthy growth in the years ahead, due to the rising awareness of people regarding animal health and increased need to prevent zoonotic and livestock-related diseases, driven by the growing need for safe and effective vaccines to protect pets, poultry, and livestock. Additionally, biotechnology is improving with discovery of recombinant and DNA-based vaccines, enhancing efficacy, safety, and production efficiency. The use of innovative delivery technology and efficient cold chain logistics is thus strengthening international access to vaccines. Such new developments are growing towards the larger picture of preventive veterinary care and sustainable livestock management, which place veterinary vaccines as a critical element to the welfare of animals and public health.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The Europe veterinary vaccines market will face a big shift based on the influence of the changing disease cycles, increased pet ownership, and a trend in veterinary care for prevention rather than treatment. In addition, there is an increased sophistication of vaccine technology, which makes it easy to apply, provide broader protection, and provide a prolonged immunogenicity response. Additionally, increasing concerns over biosecurity, tightening regulatory requirements, and low-cost mass immunization programs for livestock and shelters are changing the patterns of procurement and usage. The introduction of digital health tools, better tracking of vaccines, and wider distribution networks add to the refinement of vaccine delivery and monitoring, which is also driving revenue in the region. All in all, the Europe veterinary vaccines market is moving away from traditional vaccines toward new, more technically advanced, and cost-effective solutions for immunization.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Rise in companion animal population and pet ownership
-
Increasing incidence of infectious zoonotic diseases
Level
-
High cost of vaccine development
Level
-
Growing demand for advanced vaccines
-
Expanding livestock production
Level
-
Stringent regulatory requirements
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
EUROPE VETERINARY VACCINES MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Broad vaccine portfolio for livestock (avian influenza, bovine respiratory disease, swine fever) and pets (rabies, parvovirus) | Strong R&D in recombinant/vector vaccines | Improve livestock productivity | Reduce outbreak losses and strengthen food security | Enhance pet health |
 |
Innovative platforms, including RNA-particle and recombinant vaccines | Targeting zoonotic diseases and production animals | Broaden protection spectrum | Prolong shelf life | Better safety profile | Supports 'One Health' by reducing zoonotic risks |
 |
Poultry and swine vaccines and companion animal lines | Focus on global emerging disease threats | Reduce flock/herd mortality | Improve farmer profitability | Expand vaccine access in developing regions |
 |
Expanding livestock and companion animal vaccines with scalable production capacity | Greater vaccine availability in emerging markets | Improve farmer income | Growth in preventive pet care |
 |
Companion animal vaccines with new formulations and delivery routes | High pet vaccination compliance | Improve household disease prevention | Convenient administration |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The Europe veterinary vaccines market ecosystem covers vaccine manufacturers, such as Zoetis, MSD Animal Health (Merck), Boehringer Ingelheim, Elanco, Virbac, and Ceva. These players are the backbone of the market because of their R&D centers and vaccine manufacturing facilities spreading across Europe. It also covers regulatory authorities that help control diseases and execute mass immunization programs, while also imposing strict norms on safety, quality, and effectiveness. Lastly, end users, which include livestock and farm animal producers, are the final consumers of vaccines.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
EUROPE VETERINARY VACCINES MARKET: COMPANY EVALUATION MATRIX
In the Europe veterinary vaccines market, Zoetis (Star) is the global leader with a strong presence worldwide, a wide-ranging vaccine portfolio, and advanced technologies in the application of livestock and companion animal vaccines, ensuring rapid acceptance among commercial farms and veterinary practices. Phibro Animal Health (Emerging Leader) is now on an accelerated path with innovative vaccine solutions that are cost-effective, with an emphasis on emerging markets, as well as expanding its footprint in animal health.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Zoetis (US)
- Merck & Co, Inc. (US)
- Boehringer Ingelheim International GmbH (Germany)
- Elanco (US)
- Virbac (France)
- Ceva (France)
- Phibro Animal Health Corporation (US)
- Hester Biosciences Limited (India)
- Neogen Corporation (US)
- HIPRA (Spain)
- Biogénesis Bagó (Argentina)
- Vaxxinova International B.V. (Netherlands)
- Endovac Animal Health (US)
- Aptimmune Biologics, Inc. (US)
- Laboratoire LCV (France)
- Torigen Pharmaceuticals, Inc. (US)
WHAT IS IN IT FOR YOU: EUROPE VETERINARY VACCINES MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Product Analysis | Detailed evaluation of veterinary vaccines by type (live attenuated, inactivated, recombinant, etc.), disease target (porcine, poultry, livestock, companion animals, aquaculture), and technology | Analysis of emerging trends, such as recombinant and vector-based vaccines, multivalent and combination vaccines, marker (DIVA) vaccines, needle-free delivery systems, and thermostable formulations supporting disease control across Europe |
| Company Information | Profiles of leading players, including Zoetis, Merck Animal Health, Elanco, Boehringer Ingelheim, and Phibro, highlighting product portfolios, R&D pipelines, and market presence | Identification of strategic partnerships, EU-wide and country-level regulatory approvals, R&D collaborations, manufacturing expansions, and mergers & acquisitions influencing market competitiveness |
| Geographic Analysis |
|
Regional market outlook highlighting growth opportunities driven by increasing livestock health programs, rising companion animal vaccination rates, zoonotic disease prevention initiatives, government-supported vaccination campaigns, and harmonized EU animal health regulations |
RECENT DEVELOPMENTS
- Heading : Content
- November 2025 : Boehringer Ingelheim International GmbH launched EURICAN L4 vaccine to protect dogs against the growing threat of leptospirosis, a severe and reemerging infectious disease.
- November 2024 : Ceva invested in new vaccine manufacturing plant in Monor, Hungary. This development will establish a 7,000 m2 plant in Monor, with the most advanced technologies. In this plant, Ceva will produce fermentation-based multicomponent inactivated vaccines for animals that will help expand its global production capacity.
- September 2024 : Merck & Co., Inc. announced the expansion of its NOBIVAC NXT platform with the launch of a groundbreaking new vaccine for Feline Leukemia Virus (FeLV). This vaccine is the first and only to incorporate RNA-Particle Technology, offering a novel alternative for feline FeLV prevention.
- March 2024 : Zoetis announced the purchase of a manufacturing site in Melbourne, Australia, to significantly expand its current operations at the site and increase future capabilities to develop and manufacture vaccines for sheep, cattle, dogs, cats, and horses.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, fundamental market dynamics, and key player strategies.
Secondary Research
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, SEC filings of companies and publications from government sources [such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), American Veterinary Medical Association (AVMA), Animal Health Institute (AHI), National Animal Health Laboratory Network (NAHLN)And Food and Agriculture Organization of the United Nations (FAO)were referred to identify and collect information for the global europe veterinary vaccines market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the europe veterinary vaccines market. The primary sources from the demand side include hospitals & clinics, physiotherapy clinics and home care settings. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.
A breakdown of the primary respondents is provided below:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global europe veterinary vaccines market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/sub-segments was done for the major players (who contribute at least 70-75% of the market share at the global level). Also, the global europe veterinary vaccines market was split into various segments and sub-segments based on:
- List of major players operating in the europe veterinary vaccines products market at the regional and/or country level
- Product mapping of various europe veterinary vaccines manufacturers at the regional and/or country level
- Mapping of annual revenue generated by listed major players from europe veterinary vaccines (or the nearest reported business unit/product category)
- Revenue mapping of major players to cover at least 70-75% of the global market share as of 2023
- Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
- Summation of the market value of all segments/subsegments to arrive at the global point-of-care diagnostics market
The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.
Market Size Estimation (Bottom Up approach & Top down approach)
Data Triangulation
After arriving at the overall size of the global europe veterinary vaccines market through the above-mentioned methodology, this market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macro indicators and regional trends from both demand- and supply-side participants.
Market Definition
A veterinary vaccine is a biological preparation that provides immunity by stimulating animal’s immune system to recognize and combat specific pathogen. The europe veterinary vaccines market serves a range of vaccines such as live attenuated, inactivated, recombinant, and toxoid vaccine for a wide range of animals such as poultry, livestock, porcine, aquaculture, and companion animals. Vaccination aids in improving the health of animals, reducing the outbreak of zoonotic diseases, supporting higher productivity, and help securing economic stability.
Stakeholders
- Animal vaccine manufacturers
- Animal healthcare product manufacturers
- Animal vaccine distributors and wholesalers
- Animal welfare associations
- Veterinary clinics and care centers
- Research and consulting firms
- Veterinary Research and Development Organizations
- Contract research organizations
- Contract manufacturing organizations
- Venture capitalists
Report Objectives
- To define, measure, and describe the global europe veterinary vaccines market by type, disease, technology, route of administration, end user
- To provide detailed information about the major factors influencing the market growth (drivers, restraints, challenges, and opportunities)
- To strategically analyze the regulatory scenario, pricing, value chain analysis, supply chain analysis, ecosystem analysis, technology analysis, Porter’s Five Forces analysis, pipeline analysis and patent analysis
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of market segments in North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To strategically analyze the market structure, profile the key players in the global europe veterinary vaccines market, and comprehensively analyze their core competencies
- To track and analyze company developments such as acquisitions, partnerships, expansions, and product launches and approvals in the europe veterinary vaccines market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Europe Veterinary Vaccines Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in Europe Veterinary Vaccines Market